Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18974530 | Preparation Method and Application of Micelle Preparation Containing Thymol and Derivative Thereof | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18794128 | AMLODIPINE FORMULATIONS | August 2024 | April 2025 | Allow | 8 | 1 | 1 | No | No |
| 18600419 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | March 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18600431 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | March 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18590910 | ANALGESIC AND ANTIPRURITIC PHARMACERTICAL COMPOSITION AND APPLICATION THEREOF | February 2024 | February 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18588626 | TOPICAL FORMULATION FOR A JAK INHIBITOR | February 2024 | December 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18441397 | STABLE PHARMACEUTICAL COMPOSITIONS OF CYCLOPHOSPHAMIDE | February 2024 | January 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18528684 | STABLE PHARMACEUTICAL COMPOSITIONS OF SUCCINYLCHOLINE CHLORIDE | December 2023 | August 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18526030 | METHOD FOR IMPROVING THE SENSORIAL PROPERTIES OF OIL-IN-WATER EMULSIONS, TO REDUCE THE ADHESIVE EFFECT OF SUCH GLYCERIN-BASED OIL-IN-WATER EMULSIONS | December 2023 | February 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18487671 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION | October 2023 | April 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18478029 | AR+BREAST CANCER TREATMENT METHODS | September 2023 | February 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18455242 | TOPICAL DETOMIDINE FORMULATIONS | August 2023 | March 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18334084 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR DOWNSTREAM EFFECTORS - INDUCED CUTANEOUS REACTIONS | June 2023 | May 2025 | Abandon | 24 | 3 | 1 | No | No |
| 18022886 | Nano-Emulsion Based Compositions, Methods for Their Preparation and Their Use in Delivery of Active Ingredients | February 2023 | January 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18077296 | COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDS | December 2022 | December 2024 | Allow | 24 | 1 | 0 | No | No |
| 17942505 | PHARMACEUTICAL COMPOSITION CONTAINING B-LAPACHONE AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CHOLESTATIC LIVER DISEASE | September 2022 | May 2024 | Allow | 20 | 3 | 0 | Yes | No |
| 17820783 | METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE | August 2022 | April 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17840502 | VAPORIZABLE PSYCHOACTIVE ALKALOID COMPOSITION AND PREPARATION THEREOF | June 2022 | November 2024 | Abandon | 29 | 4 | 1 | No | No |
| 17804342 | TOPICAL TREATMENT FOR ANORECTAL DISORDERS WITH AND WITHOUT SEAT CUSHION | May 2022 | June 2025 | Abandon | 37 | 4 | 1 | Yes | No |
| 17738422 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations | May 2022 | September 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17713082 | TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORINATED ALKANES | April 2022 | March 2025 | Abandon | 35 | 3 | 1 | No | No |
| 17703543 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | March 2022 | July 2023 | Allow | 16 | 6 | 1 | Yes | No |
| 17642136 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | March 2022 | April 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17673518 | USING FATTY ACID SYNTHASE INHIBITORS TO TREAT FIBROSIS | February 2022 | November 2024 | Allow | 33 | 2 | 1 | Yes | Yes |
| 17591223 | METHODS AND COMPOSITIONS TO PREVENT AND TREAT DISORDERS ASSOCIATED WITH MUTATIONS IN THE ODC1 GENE | February 2022 | August 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17554316 | TOPICAL ACYCLOVIR FORMULATIONS AND USES THEREOF | December 2021 | March 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17496460 | METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION | October 2021 | May 2025 | Abandon | 43 | 5 | 0 | Yes | Yes |
| 17449785 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | October 2021 | March 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17292027 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | May 2021 | January 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17165652 | METHODS OF TREATING EPITHELIOID CELL TUMORS | February 2021 | September 2024 | Allow | 43 | 1 | 1 | No | No |
| 17153611 | TOPICAL DETOMIDINE FORMULATIONS | January 2021 | April 2025 | Abandon | 51 | 5 | 1 | Yes | No |
| 17052775 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | November 2020 | September 2024 | Allow | 47 | 4 | 0 | Yes | No |
| 17087365 | METHODS OF INDUCING ANESTHESIA | November 2020 | March 2025 | Abandon | 53 | 2 | 1 | Yes | Yes |
| 16971472 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | August 2020 | June 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 16932352 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | July 2020 | September 2024 | Allow | 50 | 4 | 1 | Yes | No |
| 16766019 | RHEOLOGY ADDITIVES BASED ON DI-OR TRI-AMIDES AND MIXTURES THEREOF | May 2020 | February 2024 | Allow | 45 | 4 | 1 | Yes | No |
| 16809662 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF | March 2020 | November 2024 | Abandon | 56 | 4 | 1 | Yes | No |
| 16470350 | METHOD FOR IMPROVING THE SENSORIAL PROPERTIES OF OIL-IN-WATER EMULSIONS, TO REDUCE THE ADHESIVE EFFECT OF SUCH GLYCERIN-BASED OIL-IN-WATER EMULSIONS | June 2019 | February 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16365364 | USE OF TIOTROPIUM BROMIDE TO PREVENT PULMONARY OXYGEN TOXICITY | March 2019 | February 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 16246320 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | January 2019 | June 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 15528882 | TREATMENT OF SKIN ATROPHY WITH A COMBINATION OF TRIIODOTHYROACETIC ACID (TRIAC) AND DEHYDROEPIANDROSTERONE (DHEA) | May 2017 | December 2018 | Allow | 19 | 1 | 1 | Yes | No |
| 15229116 | Therapeutic Calcium Phosphate Particles in Use for Aesthetic or Cosmetic Medicine, and Methods of Manufacture and Use | August 2016 | February 2020 | Allow | 42 | 3 | 1 | Yes | No |
| 15226415 | Formulations that Provide Support During Vaccinations and Adaptive Immune System Response | August 2016 | December 2018 | Allow | 28 | 2 | 1 | Yes | No |
| 15220617 | (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS | July 2016 | April 2019 | Allow | 33 | 2 | 1 | Yes | Yes |
| 14971230 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | December 2015 | April 2018 | Allow | 28 | 2 | 1 | No | No |
| 14704375 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL OR A NEBIVOLOL ANALOGUE | May 2015 | June 2018 | Allow | 38 | 4 | 1 | Yes | No |
| 14612143 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS | February 2015 | August 2015 | Allow | 7 | 1 | 1 | Yes | No |
| 14499457 | COMPOSITIONS AND METHODS FOR ENHANCING BRAIN FUNCTION | September 2014 | February 2016 | Allow | 17 | 0 | 0 | Yes | No |
| 14453861 | COMPOSITIONS AND METHODS FOR ENHANCING BRAIN FUNCTION | August 2014 | February 2016 | Allow | 18 | 0 | 1 | Yes | No |
| 14301757 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | June 2014 | September 2014 | Allow | 3 | 0 | 0 | Yes | No |
| 14288686 | PHARMACEUTICAL COMPOSITION | May 2014 | May 2020 | Allow | 60 | 8 | 1 | Yes | No |
| 14020363 | N-QUINOLIN-BENZENSULFONAMIDES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS AND INFLAMMATION | September 2013 | September 2017 | Allow | 48 | 4 | 1 | Yes | No |
| 13937923 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | July 2013 | November 2016 | Allow | 40 | 1 | 1 | No | No |
| 13834281 | TOPICAL PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SKIN DAMAGE | March 2013 | January 2020 | Allow | 60 | 4 | 1 | No | Yes |
| 13799682 | FORMULATION FOR THE PREVENTION OF CARDIOVASCULAR DISEASE | March 2013 | March 2019 | Allow | 60 | 4 | 1 | No | Yes |
| 13816265 | ANTI-DANDRUFF SHAMPOO | March 2013 | September 2015 | Allow | 31 | 2 | 1 | Yes | Yes |
| 13734339 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | January 2013 | July 2013 | Allow | 6 | 0 | 1 | Yes | No |
| 13706828 | COMBINATION OF 4-{3-[CIS-HEXAHYDROCYCLOPENTA[C]PYRROL-2(1H)-YL]PROPOXY}BENZAMIDE AND A NMDA RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | December 2012 | August 2014 | Allow | 21 | 1 | 1 | Yes | No |
| 13676326 | TYROSINE KINASE INHIBITORS AS ANTI-KINETOPLASTID AGENTS | November 2012 | September 2016 | Allow | 46 | 5 | 2 | No | No |
| 13610113 | COMPOSITION AND METHOD FOR THE TREATMENT OF NEURODEGENERATION | September 2012 | October 2015 | Allow | 37 | 2 | 1 | Yes | Yes |
| 13595215 | ANTIWRINKLE AGENT, LIPOLYSIS PROMOTER, EXTERNAL COMPOSITION FOR SKIN AND FOOD AND BEVERAGE COMPOSITION | August 2012 | January 2013 | Allow | 5 | 0 | 0 | No | No |
| 13541325 | INTRANASAL SPRAY DEVICE CONTAINING PHARMACEUTICAL COMPOSITION | July 2012 | March 2015 | Allow | 32 | 2 | 0 | Yes | No |
| 13541314 | METHOD OF MANAGING OR TREATING PAIN | July 2012 | February 2013 | Allow | 7 | 1 | 1 | Yes | No |
| 13539989 | PESTICIDE COMPOSITION COMPRISING PROPAMOCARB-FOSETYLATE AND AN INSECTICIDALLY ACTIVE SUBSTANCE | July 2012 | November 2014 | Allow | 28 | 2 | 1 | Yes | Yes |
| 13461063 | ASSOCIATION BETWEEN 4-{3-[CIS-HEXAHYDROCYCLOPENTA[C]PYRROL-2(1H)-YL]PROPOXY}BENZAMIDE AND AN ACETYLCHOLINESTERASE INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | May 2012 | August 2014 | Allow | 28 | 2 | 1 | Yes | Yes |
| 13378405 | NOVEL PHENYLIMIDAZOLE DERIVATIVE AS PDE10A ENZYME INHIBITOR | April 2012 | July 2014 | Allow | 31 | 2 | 1 | Yes | No |
| 13298766 | Treatment or Prevention of Fungal Infections with PDK1 Inhibitors | November 2011 | July 2014 | Allow | 32 | 1 | 1 | Yes | No |
| 13137659 | NOVEL COSMETIC COMPOSITIONS | September 2011 | September 2012 | Allow | 13 | 0 | 1 | No | No |
| 13214130 | ANTI-FUNGAL FORMULATION | August 2011 | September 2012 | Allow | 13 | 0 | 1 | No | No |
| 13098844 | PHOTOSENSITIZER COMPOSITION FOR TREATING SKIN DISORDERS | May 2011 | September 2015 | Allow | 53 | 4 | 1 | Yes | No |
| 13119736 | USE OF AZAPERONE FOR REDUCING ANTIBIOTIC USAGE | March 2011 | February 2014 | Allow | 35 | 2 | 0 | No | Yes |
| 13055005 | THERAPEUTIC AGENT FOR MIGRAINE | March 2011 | November 2015 | Allow | 58 | 4 | 1 | No | No |
| 13055206 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND THEIR USE TO TREAT MUSCLE INFLAMMATION | January 2011 | May 2015 | Allow | 52 | 3 | 1 | No | Yes |
| 13004837 | TREATING PSYCHOLOGICAL CONDITIONS USING MUSCARINIC RECEPTOR M1 ANTAGONISTS | January 2011 | July 2012 | Allow | 19 | 0 | 1 | No | No |
| 12963308 | POLYOL AND POLYETHER IRON OXIDE COMPLEXES AS PHARMACOLOGICAL AND/OR MRI CONTRAST AGENTS | December 2010 | August 2012 | Allow | 29 | 1 | 1 | Yes | No |
| 12954497 | PROCESS FOR PREPARATION OF RASAGILINE AND SALTS THEREOF | November 2010 | January 2014 | Allow | 37 | 1 | 1 | No | No |
| 12918696 | USES OF PENTAMIDINE AND RELATED COMPOUNDS | August 2010 | December 2012 | Allow | 28 | 0 | 1 | Yes | No |
| 12863513 | COMPOSITIONS AND METHODS FOR ALLEVIATING DEPRESSION OR IMPROVING COGNITION | July 2010 | March 2014 | Allow | 44 | 3 | 1 | Yes | No |
| 12833208 | COSMETIC COMPOSITIONS AND CONTAINER THEREFOR | July 2010 | February 2013 | Allow | 31 | 1 | 1 | Yes | No |
| 12774376 | PYRAZINE KINASE INHIBITORS | May 2010 | March 2011 | Allow | 11 | 0 | 1 | No | No |
| 12446567 | COMPOSITIONS AND METHODS FOR SUPPRESSING ENDOMETRIAL PROLIFERATION | April 2010 | December 2015 | Allow | 60 | 5 | 1 | No | No |
| 12750563 | ANTI-FUNGAL FORMULATION | March 2010 | March 2012 | Allow | 24 | 1 | 0 | Yes | No |
| 12705555 | ANTI-FUNGAL FORMULATION | February 2010 | April 2012 | Allow | 26 | 1 | 0 | Yes | No |
| 12689044 | CITRATE SALT OF RASAGILINE | January 2010 | October 2010 | Allow | 9 | 2 | 0 | Yes | No |
| 12590996 | PERFLUOROCARBON GEL FORMULATIONS | November 2009 | August 2012 | Allow | 33 | 0 | 1 | No | No |
| 12573322 | USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE IN THE TREATMENT OF CRANIAL TRAUMAS | October 2009 | March 2016 | Allow | 60 | 6 | 0 | Yes | Yes |
| 12450118 | SOLID PREPARATION COMPRISING 2-[[6-[(3R)-3-AMINO-1-PIPERIDINYL]-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL]METHYL]-4-FLUOROBENZONITRILE | September 2009 | March 2011 | Allow | 18 | 1 | 0 | No | No |
| 12446286 | TYROSINE KINASE INHIBITORS AS ANTI-KINETOPLASTID AGENTS | July 2009 | August 2012 | Allow | 40 | 2 | 1 | Yes | No |
| 12520808 | PESTICIDE COMPOSITION COMPRISING PROPAMOCARB-FOSETYLATE AND AN INSECTICIDALLY ACTIVE SUBSTANCE | June 2009 | May 2012 | Allow | 35 | 2 | 1 | No | No |
| 12455976 | DELAYED RELEASE RASAGILINE CITRATE FORMULATION | June 2009 | August 2011 | Allow | 26 | 1 | 0 | No | No |
| 12447065 | AQUEOUS PHARMACEUTICAL SUSPENSIONS CONTAINING REBAMIPIDE AND MANUFACTURING PROCESS THEREOF | April 2009 | February 2014 | Allow | 58 | 3 | 0 | Yes | Yes |
| 12384872 | LOW-MELTING BIOCIDAL FORMULATION | April 2009 | June 2012 | Allow | 38 | 2 | 0 | No | Yes |
| 12293877 | GALLIUM COMPOSITIONS FOR THE TREATMENT OF LIVER CANCER AND METHODS OF USE | March 2009 | October 2011 | Allow | 37 | 2 | 1 | Yes | Yes |
| 12378323 | Process for the treatment and prevention of diseases caused by fungi | February 2009 | December 2012 | Allow | 46 | 1 | 1 | Yes | No |
| 12348849 | DIHYDROXYPHENYL COMPOUNDS AND GLUCOSIDE COMPOUNDS THEREOF | January 2009 | September 2010 | Allow | 20 | 1 | 0 | No | No |
| 12206290 | INHIBITORS OF MELANOCYTE TYROSINASE AS TOPICAL SKIN LIGHTENERS | September 2008 | August 2010 | Allow | 23 | 1 | 1 | No | No |
| 12206334 | INHIBITORS OF MELANOCYTE TYROSINASE AS TOPICAL SKIN LIGHTENERS | September 2008 | March 2010 | Allow | 19 | 0 | 1 | No | No |
| 12194674 | SELF-TANNING EFFECTS | August 2008 | April 2012 | Allow | 43 | 1 | 1 | No | No |
| 12189040 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE | August 2008 | March 2010 | Allow | 20 | 0 | 0 | No | No |
| 12164137 | SUNSCREEN COMPOSITE PARTICLES AND POROUS PARTICLES IN COSMETIC COMPOSITIONS | June 2008 | March 2012 | Allow | 45 | 4 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SOROUSH, LAYLA.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 56.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SOROUSH, LAYLA works in Art Unit 1622 and has examined 115 patent applications in our dataset. With an allowance rate of 87.8%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner SOROUSH, LAYLA's allowance rate of 87.8% places them in the 64% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SOROUSH, LAYLA receive 2.67 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SOROUSH, LAYLA is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +13.4% benefit to allowance rate for applications examined by SOROUSH, LAYLA. This interview benefit is in the 55% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 18.0% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 54.5% of cases where such amendments are filed. This entry rate is in the 76% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 80.6% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 52.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 52.8% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 13.0% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.